Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3609_Библиотеки_им_академика_М_И_Перельмана
.pdf
170
ab
ab
https://t.me/medicina_free
K. Katsanos
Fig. 17.2 (a) Balloon angioplasty of the tibioperoneal artery and (b)
optimal acute angiographic result without recoil or dissection
The tibioperoneal CTO was crossed with a 0.014″
COMMAND (Abbott Vascular) guidewire supported by the 4
with a 3.0×120mm low-prole COYOTE balloon catheter
(Boston Scientic) with an optimal angiographic result
(Fig.17.2). Next, a contrast angiogram, of the foot on lateral
projection was acquired to delineate the dorsalis pedis and the
pedal arch for adequate mapping of the distal microcirculation prior to further recanalization (Fig.17.3a). The origin of
the anterior tibial artery could not be engaged (ush occlusion) and subsequently a retrograde puncture of the distal
third of the occluded left anterior tibial artery above the ankle
was performed under combined ultrasound and uoroscopic
guidance using a standard 0.018″ micropuncture kit. The
CTO was subintimally recanalized with the aid of a half- stiff
j-tipped 0.035″ Terumo glidewire until the level of the ATA
origin (Fig.17.3b). Using a rendezvous technique, a 0.014″
COMMAND guidewire with a hydrophilic tip was then
Fig. 17.3 (a) Lateral foot angiogram shows opacication of the dorsa-
lis pedis run-off vessel and a patent pedal arch while retrograde ATA
access was obtained. (b) Retrograde subintimal ATA crossing with a
j-tipped 0.035″ glidewire was performed
advanced antegradely into the ATA false lumen and navigated
into the distal dorsalis pedis true lumen. Antegrade plain balloon angioplasty of the whole ATA was performed in sequence
with 2.5×220mm and 3.0×220mm COYOTE balloon catheters with a good angiographic result and brisk ow to the
foot. The distal ATA puncture site was sealed with a prolonged 2.5mm balloon ination for 120s (Fig.17.4).
A completion angiogram of the calf and foot on lateral
and anteroposterior projection demonstrated good antegrade ow to the dorsalis pedis with a healthy pedal arch
and contrast reux into the plantar circulation (Fig.17.5).
Rest pain resolved immediately, a 6 Fr Angioseal was
deployed at the groin puncture site and the patient was discharged the same evening on a dual antiplatelet prescription (Salospir 1200mg o.d. and Clopidogrel 75mg o.d.) for
the next 6months.

17 Percutaneous Revascularization oftheTibial Arteries
https://t.me/medicina_free
171
Fig. 17.4 (a) Subintimal
dissection extended
retrogradely up to the ATA
origin, (b) next a 0.014″
COMMAND guidewire was
navigated into the false lumen
with the support of a 4 Fr
angled angiographic catheter,
(c) and a 2.5–3.0mm balloon
angioplasty of the whole ATA
down to the foot level was
performed (ination period
60s)
Fig. 17.5 Completion
angiogram of (a) the proximal
tibioperoneal and anterior
tibial arteries, (b) the distal
tibial arteries and foot (lateral
projection) and (c) the foot
(anterior projection)
demonstrating good
opacication of the dorsalis
pedis artery and pedal arch
ab c
ab c
References
1. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia.
J Vasc Surg. 2019;69:3S–125S. e140. https://doi.org/10.1016/j.
jvs.2019.02.016.
2. Hirsch AT, Haskal ZJ, Hertzer NR, etal. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic):
executive summary a collaborative report from the American
Association for Vascular Surgery/Society for Vascular Surgery,
Society for Cardiovascular Angiography and Interventions, Society
Radiology, and the ACC/AHA task force on practice guidelines
(writing committee to develop guidelines for the Management of
Patients with Peripheral Arterial Disease) endorsed by the American
Association of Cardiovascular and Pulmonary Rehabilitation;
National Heart, Lung, and Blood Institute; Society for Vascular
Nursing; TransAtlantic inter-society consensus; and vascular dis-

172
https://t.me/medicina_free
K. Katsanos
ease foundation. J Am Coll Cardiol. 2006;47:1239–312. https://doi.
org/10.1016/j.jacc.2005.10.009.
3. Spiliopoulos S, Del Giudice C, Manzi M, etal. CIRSE standards
of practice on below-the-knee revascularisation. Cardiovasc
Intervent Radiol. 2021;44:1309–22. https://doi.org/10.1007/
s00270- 021- 02891- 5.
4. Katsanos K, Kitrou P, Spiliopoulos S, etal. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated
balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network
meta-analysis of randomized controlled trials. J Endovasc Ther.
2016;23:851–63. https://doi.org/10.1177/1526602816671740.
5. Romiti M, Albers M, Brochado-Neto FC, etal. Meta-analysis of
infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc
Surg. 2008;47:975–81. https://doi.org/10.1016/j.jvs.2008.01.005.
6. Kinlay S. Management of critical limb ischemia. Circ
Cardiovasc Interv. 2016;9:e001946. https://doi.org/10.1161/
CIRCINTERVENTIONS.115.001946.
7. Prompers L, Schaper N, Apelqvist J, etal. Prediction of outcome
in individuals with diabetic foot ulcers: focus on the differences
between individuals with and without peripheral arterial disease.
The EURODIALE Study. Diabetologia. 2008;51:747–55. https://
doi.org/10.1007/s00125- 008- 0940- 0.
8. Diamantopoulos A, Patrone L, Santonocito S, etal. Carbon dioxide
angiography during peripheral angioplasty procedures signicantly
reduces the risk of contrast-induced nephropathy in patients with
chronic kidney disease. CVIR Endovasc. 2020;3:9. https://doi.
org/10.1186/s42155- 020- 0103- z.
9. Khor BYC, Price P. The comparative efcacy of angiosomedirected and indirect revascularisation strategies to aid healing of
chronic foot wounds in patients with co-morbid diabetes mellitus
and critical limb ischaemia: a literature review. J Foot Ankle Res.
2017;10:26. https://doi.org/10.1186/s13047- 017- 0206- 5.
10. Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for
Vascular Surgery Lower Extremity Threatened Limb Classication
System: risk stratication based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59:220–34. https://doi.org/10.1016/j.
jvs.2013.08.003.
11. Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional
Radiology Consensus Guidelines for the Periprocedural
Management of Thrombotic and Bleeding Risk in patients undergoing percutaneous image-guided interventions-part II: recommendations: endorsed by the Canadian Association for Interventional
Radiology and the Cardiovascular and Interventional Radiological
Society of Europe. J Vasc Intervent Radiol JVIR. 2019;30:1168–84.
https://doi.org/10.1016/j.jvir.2019.04.017.
12. van der Molen AJ, Reimer P, Dekkers IA, etal. Post-contrast acute
kidney injury. Part 2: risk stratication, role of hydration and other
prophylactic measures, patients taking metformin and chronic
dialysis patients: recommendations for updated ESUR Contrast
Medium Safety Committee guidelines. Eur Radiol. 2018;28:2856–
69. https://doi.org/10.1007/s00330- 017- 5247- 4.
13. Kitrou P, Parthipun A, Diamantopoulos A, et al. Targeted true
lumen re-entry with the outback catheter: accuracy, success, and
complications in 100 peripheral chronic total occlusions and systematic review of the literature. J Endovasc Ther. 2015;22:538–45.
https://doi.org/10.1177/1526602815594249.
14. Bazan HA, Le L, Donovan M, etal. Retrograde pedal access for
patients with critical limb ischemia. J Vasc Surg. 2014;60:375–81.
https://doi.org/10.1016/j.jvs.2014.02.038.
15. Biagioni RB, Biagioni LC, Nasser F, et al. Infrapopliteal angioplasty of one or more than one artery for critical limb ischaemia: a
randomised clinical trial. Eur J Vasc Endovasc Surg. 2018;55:518–
27. https://doi.org/10.1016/j.ejvs.2017.12.022.
16. Alexandrescu V, Hubermont G. The challenging topic of diabetic
foot revascularization: does the angiosome-guided angioplasty may
improve outcome. J Cardiovasc Surg. 2012;53:3–12.
17. Katsanos K, Spiliopoulos S, Kitrou P, etal. Risk of death following
application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of
randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
https://doi.org/10.1161/JAHA.118.011245.
18. Katsanos K, Spiliopoulos S, Teichgraber U, et al. Editor’s
choice—risk of major amputation following application of paclitaxel coated balloons in the lower limb arteries: a systematic
review and meta- analysis of randomised controlled trials. Eur J
Vasc Endovasc Surg. 2022;63:60–71. https://doi.org/10.1016/j.
ejvs.2021.05.027.
19. Katsanos K, Spiliopoulos S, Diamantopoulos A, et al. Wound
healing outcomes and health-related quality-of-life changes in
the ACHILLES trial: 1-year results from a prospective randomized controlled trial of infrapopliteal balloon angioplasty versus
sirolimus-eluting stenting in patients with ischemic peripheral arterial disease. JACC Cardiovasc Interv. 2016;9:259–67. https://doi.
org/10.1016/j.jcin.2015.10.038.
20. Scheinert D, Katsanos K, Zeller T, etal. A prospective randomized
multicenter comparison of balloon angioplasty and infrapopliteal
stenting with the sirolimus-eluting stent in patients with ischemic
peripheral arterial disease: 1-year results from the ACHILLES trial.
J Am Coll Cardiol. 2012;60:2290–5. https://doi.org/10.1016/j.
jacc.2012.08.989.
21. Katsanos K, Spiliopoulos S, Diamantopoulos A, et al. Systematic
review of infrapopliteal drug-eluting stents: a meta-analysis
of randomized controlled trials. Cardiovasc Intervent Radiol.
2013;36:645–58. https://doi.org/10.1007/s00270-013-0578-2.
22. Kum S, Ipema J, Chun-Yin DH, etal. Early and midterm experience with the absorb everolimus-eluting bioresorbable vascular scaffold in Asian patients with chronic limb-threatening
ischemia: 1-year clinical and imaging outcomes from the
DISAPEAR registry. J Endovasc Ther. 2020;27:616–22. https://doi.
org/10.1177/1526602820922524.
23. Diamantopoulos A, Katsanos K.Atherectomy of the femoropopliteal artery: a systematic review and meta-analysis of randomized
controlled trials. J Cardiovasc Surg. 2014;55:655–65.
24. Katsanos K, Spiliopoulos S, Reppas L, et al. Debulking atherectomy in the peripheral arteries: is there a role and what is the evidence? Cardiovasc Intervent Radiol. 2017;40:964–77. https://doi.
org/10.1007/s00270- 017- 1649- 6.
25. Shammas NW.Current role of atherectomy for treatment of femoropopliteal and infrapopliteal disease. Intervent Cardiol Clin.
2017;6:235–49. https://doi.org/10.1016/j.iccl.2016.12.007.
26. Lichtenberg M, Schreve MA, Ferraresi R, etal. Surgical and endovascular venous arterialization for treatment of critical limb ischaemia. VASA Zeitschrift fur Gefasskrankheiten. 2018;47:17–22.
https://doi.org/10.1024/0301- 1526/a000669.
27. Schmidt A, Schreve MA, Huizing E, etal. Midterm outcomes of
percutaneous deep venous arterialization with a dedicated system
for patients with no-option chronic limb-threatening ischemia: the
ALPS multicenter study. J Endovasc Ther. 2020;27:658–65. https://
doi.org/10.1177/1526602820922179.
28. Arkoudis NA, Katsanos K, Inchingolo R, etal. Quantifying tissue perfusion after peripheral endovascular procedures: novel tissue perfusion endpoints to improve outcomes. World J Cardiol.
2021;13:381–98. https://doi.org/10.4330/wjc.v13.i9.381.
29. Tsigkas G, Apostolos A, Trigka A, etal. Very short versus longer
dual antiplatelet treatment after coronary interventions: a systematic
review and meta-analysis. Am J Cardiovasc Drugs. 2023;23:35–46.
https://doi.org/10.1007/s40256- 022- 00559- 0.
30. Katsanos K, Spiliopoulos S, Saha P, etal. Comparative efcacy and
safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral
arterial disease: a systematic review and network meta-analysis.
PLoS One. 2015;10:e0135692. https://doi.org/10.1371/journal.
pone.0135692.

Interventions forPedal Disease
https://t.me/medicina_free
StavrosSpiliopoulos
18
Case Presentation
A 71-year-old male, ex-smoker, with a history of longstanding type II insulin-dependent diabetes mellitus (IDDM),
hypercholesterolemia, coronary disease, and hypertension,
was presented to the hospital complaining of right foot rest
pain as well as worsening rst and second toes, and heal dry
gangrene, for at least 3 months. Pedal pulses were absent,
ankle-brachial index (ABI) was 0.55, and duplex ultrasound
revealed occlusion of all three infrapopliteal vessels, without
iliac, and femoropopliteal inow disease. The diagnosis was
chronic limb-threatening ischemia, CLTI category 5 according to Rutherford–Becker. The patient was placed on antiplatelet therapy and was discussed at the vascular
multi-disciplinary team meeting (MDT). Based on the
comorbidities, clinical presentation, the infrapopliteal location of the disease, as well as the fact that his eGFR was
44 mL/min/1.73 m2, the MDT decision was to skip
CT-angiography and proceed immediately to antegrade DSA
from a common femoral artery (CFA) access, with a view to
same-session endovascular treatment. Endovascular treatment was performed 2days after presentation.
Continued at page 176
Background
Infrapopliteal arterial and pedal arch steno-occlusive disease
commonly affects subjects with diabetes leading to progressive deterioration of foot perfusion and eventually to tissue
loss with or without gangrene dened as chronic limbthreatening ischemia (CLTI), which without prompt revascularization will eventually lead to limb loss and increased
1-year mortality risk [1]. Notably, CLTI patients demonstrate
signicantly higher mortality rates compared to those with
S. Spiliopoulos (*)
2nd Department of Radiology, National and Kapodistrian
University of Athens, “ATTIKON” University General Hospital,
Athens, Greece
e-mail: stavspiliop@med.uoa.gr
symptomatic coronary artery disease, while major amputation has been recognized as a major contributing factor of
quality-of-life deterioration and increased mortality risk [2,
3]. Generally, the diagnosis is set by clinical symptoms
(absence of peripheral pulses, rest pain, tissue loss/gangrene
>2weeks duration), but it can also be supported by hemodynamic tests such as abnormal ABI or toe-brachial index
(TBI) for diabetic patients, abnormal tissue perfusion evaluation (TcPO2 ≤30 mmHg), and imaging ndings (duplex
ultrasound, CT- or MR-angiography) [4]. In specialized vascular centers, percutaneous endovascular procedures—
mainly infrapopliteal angioplasty or stenting—and open
surgical distal venous bypass procedures are the standard of
practice for CLTI patients requiring revascularization [1, 5].
The choice of revascularization type (endovascular or open)
should be individualized and decided by a vascular MDT
based on distinct patient and lesion characteristics. However,
as endovascular procedures are less invasive and provide
valid clinical outcomes, without excluding future surgical
options, the “endovascular rst” approach is currently used
in most CLTI patients with tibial arterial disease [6–8]. In
recent years, endovascular specialists, driven by increasing
clinical experience, and supported by the signicant technological advances of endovascular materials and devices, have
advanced even more distally, from crural vessel treatment to
pedal arch angioplasty [9]. In fact, endovascular pedal reconstruction is currently the only treatment option for pedal arch
steno-occlusive atherosclerotic disease, as to date there is no
feasible surgical method to reconstruct the pedal arch.
Indications forIntervention [10]
• Rest pain (Rutherford category 4) and/or non-healing
ulcer/gangrene (Rutherford categories 5–6)
• Non-healing ischaemic ulcer following amputation
• Salvage run-off treatment in failing surgical bypass
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2024
G. Geroulakos et al. (eds.), Mastering Endovascular Techniques, https://doi.org/10.1007/978-3-031-42735-0_18
173

174
https://t.me/medicina_free
S. Spiliopoulos
Preoperative Preparation
Timing ofIntervention
For subjects with diabetes and CLTI (diabetic foot), emergency revascularization (open, endovascular, or hybrid)
should be offered to prevent superinfection and decrease
major amputation risk.
Laboratory Tests
Baseline full blood count, renal function (eGFR), glucose,
electrolytes, and coagulation prole should be available.
Ideally, platelet count should be >50,000/mcL and INR <1.5.
Compromised renal function (eGFR<60 mL/min) requires
parenteral saline infusion (1.0–1.5mL/kg/h), 6h before and
6–12h after the procedure, or intravenous sodium bicarbonate as an alternative, while metformin intake should be discontinued for 48 h prior to and after the procedure and
re-initiated if eGFR is stable, to avoid lactic acidosis [11].
Non-iodine contrast media alternatives such as carbon dioxide (CO2) may be used, but adequate analgesia/sedation or
general anaesthesia should be considered, as pedal CO2
administration can be very painful.
Drug Therapy
location and extent of the crural disease and assist in preprocedural planning during the MDT. Although CTA has
known diagnostic limitations in the ambit of distal crural
vessels, especially in the presence of calcications, it is an
indispensable pre-procedural tool, as it allows for inow
lesions detection and optimal access-site evaluation. On the
other hand, dedicated pedal MRA, with or without contrast
enhancement, demonstrates excellent results in outow vessel detection in diabetic patients, even in the presence of
more proximal stenosis [12, 13]. DUS of the access site and
the distal pedal vessels can be extremely useful for preprocedural limb evaluation within the angio suite before
obtaining access for pedal arch angioplasty.
Endovascular Strategy andTechnique
Basic Endovascular Toolkit
• Standard arterial sheaths 4–6 Fr in diameter and 10–45cm
in length
• Long-shaft balloon catheters—commonly 1.5–3.0mm of
various lengths/tapered balloon catheters
• Dedicated below-the-knee 0.014″/0.018″-inch 300 cm
guidewires
• Supporting/crossing 0.014″/0.018″ catheters
Warfarin should be discontinued for 3days (usually sufcient for INR normalization) and heparin may be given as
bridging therapy according to local hospital policy. Dual
antiplatelet therapy with clopidogrel 75mg and acetylsalicylic acid (ASA) 100mg once daily at least 3days before the
procedure is a generally acceptable antiplatelet protocol to
inhibit platelet function. Alternatively, a loading dose of
Clopidogrel 300 mg 12 h before the procedure could be
administrated in patients at low bleeding risk. However, the
level of evidence to support pre-procedural antithrombotic
therapy is low [10]. In the presence of infected wound/gangrene, intravenous antibiotic therapy should be administrated
well before the attempt to revascularize the infected foot, so
as to avoid bacteremia and sepsis. Antihypertensive therapy
should be continued the day of the procedure to reduce
access-site bleeding risk. Statins should be prescribed, even
in patients with normal lipidic prole (low-dose statins) as it
has been shown to decrease cardiovascular death risk in subjects with cardiovascular disease and diabetes [1].
Imaging
Duplex ultrasound (DUS), CTA, or MRA is essential not
only to establish diagnosis, but also to depict the anatomic
Access andCrossing theLesion
An antegrade CFA access is recommended for pedal arch
interventions, mainly due to pushability, torquability, and
length issues of the catheters and guidewires, especially if a
“plantar-loop” revascularization technique is anticipated.
Ultrasound-guided lidocaine (1–2%) injection and puncture
of the CFA can reduce access-site related pain and complication rates. Access can be obtained with micropuncture sets or
directly with standard 18–19 G needles and 0.035′ guidewires, especially in hostile abdomens, where a direct puncture of the SFA, below the level of the femoral head, can be
considered. In such cases, the use of a closure device to avoid
bleeding complications is advised [14]. Standard 4–6 Fr and
10–45cm arterial sheaths can be used. Most interventions
are performed under local anesthesia and conscious sedation
and general anesthesia is reserved for selected cases of
patients unable to cooperate. Intra-arterial bolus heparin
3000–5000IU is usually administrated via the sheath following access, while nitro-glycerine (1μg in 10mL of saline)
can be used locally to reduce spasm during guidewire manipulations and balloon ination.
An antegrade intraluminal recanalization attempt with a
0.014″ system should be performed rst. Pedal angioplasty

18 Interventions forPedal Disease
https://t.me/medicina_free
175
is performed after descending the anterior or posterior tibial
artery and navigating the guidewire across the pedal-plantar
loop with or without the “plantar-loop” technique (e.g., retrograde recanalization of the anterior tibial after descending
the posterior tibial and across the arch, or vice versa). The
uoroscopic projections during pedal arch navigation include
both the ipsilateral cranial-antero-posterior (image intensier parallel to the foot dorsum to allow imagining of the rst
metatarsal space) and the contra-lateral oblique (“Charlie
Chaplin” projection) for the visualization of the connection
dorsalis pedis-deep perforating artery-pedal arch, and the
bifurcation of the common plantar artery [15]. Prolonged,
3–6 frames per sec, selective DSA imaging, after nitroglycerin administration, is recommended for the accurate visualization of collateral network and target vessels and to
minimize motion artifact. Dedicated infrapopliteal angled
hydrophilic guidewires 0.014′ in diameter and 300mm in
length are recommended for steerability during arch navigation, supported by 2–2.5mm infrapopliteal low-prole balloons or dedicated 0.014″ microcatheter systems, which also
enable selective contrast injection and roadmap use to guide
arch crossing, avoiding side-branches. Of note, straight
guidewires can also be used, depending on the anatomy,
which can also be bended accordingly to allow “individualized” arch navigation. Support catheters measuring 0.018″
can be used for initial CTO crossing as this enables easier
guidewire exchange and better selective angiographic imaging. Low-weight CTO 0.014′ or 0.018″ hydrophilic guidewires can also be used for initial access within the occlusion,
subsequently exchanged with normal-weight guidewires for
around the arch navigation. Notably, subintimal recanalization of the entire pedal arch is not indicated at it would result
in occlusion of the digital arteries, resulting in aggravating
ischemia. Therefore, guidewire manipulation must be gentle,
preferably using torque movements and gentle pressure for
advancement, rather than strong pushing. In cases of antegrade intraluminal recanalization failure, an additional
ultrasound- guided retrograde pedal puncture and retrograde
lesion crossing with the SAFARI technique can be attempted,
using dedicated pedal access or micropuncture sets [16].
Nominal pressure, prolonged 2–4 min ination is recommended to achieve maximum luminal gain and minimize
dissections. Small 1.5–2mm diameter short-length (20mm)
balloon catheters can be used for initial crossing and dilation
of hard atherosclerotic lesions, subsequently upsized accordingly. Finally, if lesion crossing with a balloon is not feasible, usually due to hard calcied lesions, orbital atherectomy
could be considered, by analogy to coronary lesions. The use
of metallic stents is not recommended due to fracture and
deformation issues correlated with vessel occlusion and
amputation, while the use of paclitaxel-coated balloons is
not supported by evidence and safety issues have also been
raised [17–19].
Results
Over the past decade, several authors have reported excellent
technical success rates (up to 96%), and pedal arch revascularization has been reported as an independent factor for
faster wound healing [9, 20, 21]. However, prospective randomized trials to support the clinical superiority of pedal
arch angioplasty versus conventional infrapopliteal angioplasty are missing from the literature. Current data from a
2019 meta-analysis of 10 studies (478 patients with belowthe- ankle angioplasty in 524 legs) indicate that the 1-year
limb salvage rate following pedal arch angioplasty is 92%.
However, the level of evidence was low [22].
Anticipated Complications
Procedure-related complications related to guidewire manipulations and balloon ination are vessel spasm, dissection,
thromboembolism, and rupture. Vessel spasm can be managed with nitro-glycerine locally. Prolonged 3–5min lowpressure balloon ination can be applied in cases of
ow-limiting dissection and vessel rupture.
Thromboembolism is extremely rare during sole pedal arch
angioplasty and standard rt-PA thrombolysis with or without
catheter thrombo-aspiration can be employed. Finally, standard access-site complications, mainly retroperitoneal bleeding, pseudoaneurysm, and arteriovenous stula formation,
are also anticipated.
Perioperative Care andSurveillance
In cases of 6 Fr sheath access, vascular closure devices
should be available to reduce bleeding complications in
selected cases, but also to accelerate patient ambulation.
Haemostasis following pedal access can be obtained following 5–10min of manual compression. Peripheral interventions can be performed on an outpatient basis. Access-site
and vital signs monitoring is suggested until discharge. In the
absence of adverse events, light diet is suggested after 4–5h
and discharge after approximately 8h. Postprocedural medical therapy should include statins (low dose in cases of normal cholesterol plasma levels), antihypertensive therapy,
optimal glycemic prole, and per os antithrombotic therapy
[23]. Evidence regarding antithrombotic therapy following
infrapopliteal plus pedal revascularization remains limited
and a personalized approach, considering the bleeding ischemic risk ratio, is recommended. Standard protocols following complex BTK revascularization include 6-month dual
antiplatelet therapy with clopidogrel 75mg and ASA 75mg
or 100 mg once daily, followed by life-long clopidogrel
monotherapy or rivaroxaban 2.5mg twice daily and ASA

176
https://t.me/medicina_free
S. Spiliopoulos
100 mg once daily (especially in patients with coronary
artery disease at low bleeding risk) [10]. Meticulous wound
care and strict follow-up protocols are recommended following complex BTK and pedal procedures. DUS before discharge and clinical visits at 1, 3, 6, and 12 months are
recommended, including surveillance with ABI/TBI, transcutaneous oxygen pressure (TcPO2), and DUS.
Case Presentation
Continued from page 173
The procedure was performed under local anesthesia
(US-guided) and iv fentanyl (100μg in two doses) for pain
relief. Antegrade US-guided access with a 6 Fr × 10cm arterial sheath was obtained followed by bolus administration of
5.000IU of unfractionated heparin. Selective infrapopliteal
DSA conrmed the diagnosis of diffuse 3-vessel (Fig.18.1a)
and pedal arch (Fig.18.1b) atherosclerotic steno-occlusive
disease. Specically, signicant tandem stenosis and focal
occlusions were noted along the ATA, pedal artery, and pedal
arch. Tandem stenosis and occlusion of the distal third of the
peroneal and posterior tibial arteries were noted, while the
medial and lateral plantar arteries appeared occluded. A 5 Fr
× 65 cm curved catheter (Vanscie 1, Cook, UK) and a
0.014″/300cm straight guidewire (ASAHI Regalia® XS 1.0,
Japan) were used to negotiate the origin of the ATA and,
using the above-mentioned uoroscopic projections
(Fig.18.2a, b), the guidewire was advanced through the tandem lesions and nally positioned at the mid-pedal artery.
ab
Fig. 18.1 Selective infrapopliteal DSA with the diagnostic catheter
positioned at the distal popliteal artery demonstrating diffuse infrapopliteal 3-vessel (a) and pedal arch (b) atherosclerotic steno-occlusive
disease
Fig. 18.2 (a) Ipsilateral,
cranial, anteroposterior
projection for guidewire
navigation from the anterior
(pedal artery) to the posterior
circulation (lateral plantar
artery) via the deep
perforating artery. (b)
Contralateral “Charlie
Chaplin” projection to
navigate around the arch to
the common plantar artery
and the posterior tibial artery
a b

ab
18 Interventions forPedal Disease
https://t.me/medicina_free
abc
177
Fig. 18.3 2.5mm balloon angioplasty of the pedal artery (a) and the plantar arch (b). The guidewire could not cross the proximal plantar artery
occlusion (c)
Balloon angioplasty of the ATA/pedal artery was performed
using a 150mm shaft, 3 × 150 mm, 0.014″ compatible balloon catheter (Coyote, Boston Scientic, USA). The balloon
catheter was then exchanged over the wire with a 2.5 ×
100mm balloon catheter (Coyote, Boston Scientic, USA),
used to support the navigation of the guidewire across the
pedal arch and the pedal-plantar loop, and retrograde intraluminal recanalization of the lateral plantar artery occlusion, as
well as pedal arch-plasty, was performed using the same
2.5 mm balloon (“plantar-loop” technique) (Fig. 18.3a–c).
The guidewire was subsequently retrieved from the ATA and
the posterior tibial artery, including its distal segment, was
recanalized with the 2.5 × 100 mm balloon distally
(Fig.18.4a, b) and the 3 × 150mm balloon more proximally.
Final DSA demonstrated a satisfactory angiographic outcome with two-vessel run-off and complete pedal arch
reconstruction (Fig. 18.5). The patient reported immediate
pain relief. Complete wound healing was noted at 6months
follow-up.
Fig. 18.4 The posterior tibial and common plantar arteries were revascularized using the antegrade approach with a 2.5mm balloon catheter

178
https://t.me/medicina_free
Fig. 18.5 Selective pre- (a)
and (b) post-angioplasty DSA
images
S. Spiliopoulos
References
1. Bailey SR, Beckman JA, Dao TD, et al. ACC/AHA/SCAI/SIR/
SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American College of Cardiology Appropriate
use Criteria Task Force, American Heart Association, Society
for Cardiovascular Angiography and Interventions, Society of
Interventional Radiology, and Society for Vascular Medicine. J Am
Coll Cardiol. 2019;73(2):214–37.
2. Teraa M, Conte MS, Moll FL, Verhaar MC. Critical limb ischemia: current trends and future directions. J Am Heart Assoc.
2016;5:e002938.
3. Katsanos K, Spiliopoulos S, Diamantopoulos A, Siablis D,
Karnabatidis D, Scheinert D.Wound healing outcomes and healthrelated quality-of-life changes in the ACHILLES trial: 1-year
results from a prospective randomized controlled trial of infrapopliteal balloon angioplasty versus sirolimus-eluting stenting in
patients with ischemic peripheral arterial disease. JACC Cardiovasc
Interv. 2016;9(3):259–67.
4. Conte MS, Bradbury AW, Kolh P, GVG Writing Group, etal. Global
vascular guidelines on the management of chronic limb-threatening
ischemia. J Vasc Surg. 2019;69(6S):3S–125S.e40.
5. Elbadawy A, Ali H, Saleh M, Hasaballah A.A prospective study
to evaluate complete wound healing and limb salvage rates
after angiosome targeted infrapopliteal balloon angioplasty in
patients with critical limb ischaemia. Eur J Vasc Endovasc Surg.
2018;55(3):392–7.
6. Feldman ZM, Mohapatra A.Endovascular management of complex
tibial lesions. Semin Vasc Surg. 2022;35(2):190–9.
7. Hicks CW, Canner JK, Lum YW, Black JH 3rd, Abularrage
CJ.Long-term outcomes of an endovascular-rst approach for diabetic patients with predominantly tibial disease treated in a multidisciplinary setting. Ann Vasc Surg. 2019;60:315–326.e2.
8. Faglia E, Dalla Paola L, Clerici G, etal. Peripheral angioplasty
as the rst-choice revascularization procedure in diabetic patients
with critical limb ischemia: prospective study of 993 consecutive
patients hospitalized and followed between 1999 and 2003. Eur J
Vasc Endovasc Surg. 2005;29(6):620–7.
9. Jung HW, Ko YG, Hong SJ, et al. Editor’s choice—impact of
endovascular pedal artery revascularisation on wound healing in
patients with critical limb Ischaemia. Eur J Vasc Endovasc Surg.
2019;58(6):854–63.
10. Spiliopoulos S, Del Giudice C, Manzi M, Reppas L, Rodt T, Uberoi
R.CIRSE standards of practice on below-the-knee revascularisation. Cardiovasc Intervent Radiol. 2021;44(9):1309–22.
11. van der Molen AJ, Reimer P, Dekkers IA, etal. Post contrast acute
kidney injury—part 1: denition, clinical features, incidence, role
of contrast medium and risk factors: recommendations for updated
ESUR Contrast Medium Safety Committee guidelines. Eur Radiol.
2018;28(7):2845–55.
12. Chomel S, Douek P, Moulin P, Vaudoux M, Marchand B.Contrastenhanced MR angiography of the foot: anatomy and clinical
application in patients with diabetes. AJR Am J Roentgenol.
2004;182(6):1435–42.
13. Schubert T, Takes M, Aschwanden M. Non-enhanced, ECGgated MR angiography of the pedal vasculature: comparison
with contrast-enhanced MR angiography and digital subtraction
angiography in peripheral arterial occlusive disease. Eur Radiol.
2016;26(8):2705–13.
14. Spiliopoulos S, Kitrou P, Christeas N, Karnabatidis D.Starclose
SE® hemostasis after 6F direct antegrade supercial femoral
artery access distal to the femoral head for peripheral endovascular procedures in obese patients. Diagn Interv Radiol.
2016;22(6):542–7.
15. Manzi M, Cester G, Palena LM, Alek J, Candeo A, Ferraresi
R.Vascular imaging of the foot: the rst step toward endovascular
recanalization. Radiographics. 2011;31(6):1623–36.
16. Stahlberg E, Stroth A, Haenel A, Grzyska U, Wegner F, Sieren M,
Horn M, Barkhausen J, Goltz JP.Retrograde revascularization of
tibial arteries in patients with critical limb ischemia: plantar-arch
versus transpedal approach. J Endovasc Ther. 2022;29(2):181–92.

18 Interventions forPedal Disease
https://t.me/medicina_free
179
17. Karnabatidis D, Katsanos K, Spiliopoulos S, Diamantopoulos A,
Kagadis GC, Siablis D.Incidence, anatomical location, and clinical
signicance of compressions and fractures in infrapopliteal balloonexpandable metal stents. J Endovasc Ther. 2009;16(1):15–22.
18. Katsanos K, Spiliopoulos S, Teichgräber U.Editor’s choice—risk
of major amputation following application of paclitaxel coated
balloons in the lower limb arteries: a systematic review and metaanalysis of randomised controlled trials. Eur J Vasc Endovasc Surg.
2022;63(1):60–71.
19. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Paraskevopoulos
I, Karnabatidis D. Risk of death and amputation with use of
paclitaxel- coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and metaanalysis of randomized controlled trials. J Vasc Interv Radiol.
2020;31(2):202–12.
20. Nakama T, Watanabe N, Haraguchi T, etal. Clinical outcomes of
pedal artery angioplasty for patients with ischemic wounds: results
from the multicenter RENDEZVOUS registry. JACC Cardiovasc
Interv. 2017;10:79–90.
21. Meyer A, Schinz K, Lang W, Schmid A, Regus S, Rother
U. Outcomes and inuence of the pedal arch in below-the-knee
angioplasty in patients with end-stage renal disease and critical
limb ischemia. Ann Vasc Surg. 2016;35:121–9.
22. Huizing E, Schreve MA, de Vries JPM, Ferraresi R, Kum S, Ünlü
Ç. Below-the-ankle angioplasty in patients with critical limb ischemia: a systematic review and meta-analysis. J Vasc Interv Radiol.
2019;30(9):1361–1368.e2.
23. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/
ACC guideline on the management of patients with lower extremity
peripheral artery disease: executive summary. J Am Coll Cardiol.
2017;69(11):1465–508.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
